Nexalin Technology (NXL) Current Deferred Revenue (2021)
Nexalin Technology (NXL) recorded quarterly Current Deferred Revenue of $130000.0 in Q4 2021.
Nexalin Technology (NXL) Current Deferred Revenue (2021) Analysis & Trends
Nexalin Technology's Current Deferred Revenue history runs 1 years deep, the most recent figure standing at $130000.0 for Q4 2021.
- In Q4 2021, Current Deferred Revenue changed N/A year-over-year to $130000.0; the TTM figure through Dec 2021 stood at $130000.0 (changed N/A YoY), while the FY2021 annual figure was $130000.0, changed N/A from the prior year.
- Current Deferred Revenue was $130000.0 for Q4 2021 at Nexalin Technology.
- In the past five years, Current Deferred Revenue ranged from a high of $130000.0 in Q4 2021 to a low of $130000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn |
| 10 | Nexalin Technology | 7.82 Mn | 5.11 Mn | 13,133.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 130,000.00 |